Prevention of calcification with TPEN in pericardial bioprosthetic heart valve material

Anadolu Kardiyoloji Dergisi

Volumn 7, Issue 4, 2007, Pages 365-370

  Ali Dondas H ^a   Yilmaz, Nejat ^a   Çömelekoǧlu, Ülkü ^a   Tamer, Lülüfer ^a   Sucu, Nehir ^a   Aytaçoǧlu, Barlas N ^a   Özeren, Murat ^a   Köse, Necmi ^a   Dikmengil, Murat ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Bioprosthetic heart valve; Calcification; Glutaraldehyde; TPEN

Indexed keywords

CALCIUM; GLUTARALDEHYDE; N,N,N',N' TETRAKIS(2 PYRIDYLMETHYL)ETHYLENEDIAMINE; PHOSPHATE BUFFERED SALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; CALCIFICATION; CONTROLLED STUDY; COW; EXPLANT; HEART VALVE BIOPROSTHESIS; HISTOPATHOLOGY; LOW TEMPERATURE; MALE; NONHUMAN; PERICARDIUM; PH MEASUREMENT; RAT; STATISTICAL SIGNIFICANCE; STRESS STRAIN RELATIONSHIP; TEMPERATURE MEASUREMENT; TENSILE STRENGTH; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; BIOPROSTHESIS; CALCINOSIS; CALCIUM; CATTLE; CHELATING AGENTS; ETHYLENEDIAMINES; HEART VALVE PROSTHESIS; MALE; PERICARDIUM; RATS; RATS, WISTAR; TENSILE STRENGTH; TISSUE FIXATION;

EID: 37349019697     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg 2005; 79: 1072-80.
2. Simionescu D T. Prevention of calcification in bioprosthetic heart valves: challenges and perspectives. Expert Opin Biol Ther 2004; 12: 1971-85.
3. Schoen FJ, Harasaki H, Kim KM, Anderson HG, Levy RJ. Biomaterials associated calcification. Pathology, mechanism, and strategies for prevention. J Biomed Mat Res 1988; 22: 11-36.
4. Levy RJ, Schoen FJ, Rowers WB, Staelins J. Initiation mineralization in bioprosthetic heart valves. Studies of alkaline phosphatase activity and its inhibition by ALCL3 or FeCL3 preincubations. J Biomed Mat Res 1991; 25: 905-35.
5. Hirsch D, Schoen FJ, Levy RJ. The effects of metallic ions and diphosphonates on inhibition of pericardial bioprosthetic tissue calcification and associated alkaline phosphatase activity. Biomaterials 1992; 14: 371-7.
6. Hirsch D, Drader J, Thomas TJ, Schoen FJ, Levy JT, Levy RJ. Inhibition of calcification of glutaraldehyde pretreated porcine aortic valve cusps with sodium dodecyl sulfate: preincubation and controlled release studies. J Biomed Mater Res 1993; 27: 1477-84.
7. Webb CL, Benedict JJ, Schoen FJ, Linden JA, Lew RJ. Inhibition of bioprosthetic heart valve calcification with aminodiphosphonates covalently bound to residual aldehyde groups Ann Thorac Surg 1988; 46: 309-16.
8. Vasudev SC, Chandy T, Sharma CP, Monathy M, Umasankar PR. Synergistic effect of released aspirin/heparin for preventing bovine pericardial calcification. Artificial Organs 2000; 24: 129-36.
9. Shen M, Kara-Mostefa A, Chen L, Daudon M, Thevenin M, Lacour B, et al. Effect of ethanol and ether in prevention of calcification of bioprosthesis. Ann Thorac Surg 2001; 71: 413-6.
10. Valente M, Pettenazzo E, Thiene G, Molin GM, Martignago F, De Giorgi G, et al. Detoxified glutaraldehyde cross-linked pericardium: Tissue preservation and mineralization mitigation in a subcutaneous rat model. J Heart Valve Dis 1998; 7: 283-91.
11. Abolhoda A, Yu S, Oyarzun JR, Allen KR, McCormick JR, Han S et al. No-React detoxification process: A superior anticalcification method for bioprosthesis. Ann Thorac Surg 1996; 62: 1724-30.
12. Grabenwöger M, Sider J, Fitzal F Zelenka C, Windberger U, Grimm M et al. Impact of glutaraldehyde on calcification of pericardial bioprosthetic heart valve material. Ann Thorac Surg 1996; 62: 772-7.
13. Sucu N, Tamer L, Dondas HA, Polat A, Aytacoglu B, Cimen MY, et al. The effect of ethylenediaminetetraacetic acid on calcific degeneration in bovine pericardium. Heart Vessels 2004; 19: 89-93.
14. Sucu N, Tamer L, Aytacoglu B Polat A, Dondas HA, Gul A, et al. Inhibition of calcification with citric acid in pericardial bioprosthetic heart valve material: a preliminary report. J Heart Valve Dis 2004; 13: 697-700.
15. Arslan P, Di-Virgilio F, Beltrame M, Tsien RY, Pozzan T. Cytosolic Ca+2 homeostasis in Ehrlich and Yoshida carcinomas. A new, membrane-permeant chelator of heavy metals reveals that these ascites tumor cell lines have normal cytosolic free Ca+2. J. Biol. Chem 1985; 260: 2719-27.
16. Shmist YA, Kamburg R, Ophir G, Kozak A, Shneyvays V, Appelbaum YJ, et. al. N,N,N′,N′-Tetrakis(2-pyridylmethyl)-ethylenediamine improves myocardial protection against ischemia by modulation of intracellular Ca+2 homeostasis. J Pharmacol Exp Ther 2005; 313: 1046-57.
17. Parker HE. Magnesium, Calcium and Zinc in animal nutrition. At Absorb Newslet 1963; 2: 23-7.
18. Schoen F J, Lew R J, Nelson AC, Bernhard WF, Nashef A, Hawlley M. Onset and progression of experimental bioprosthetic heart valve calcification. Lab Invest 1985; 52: 523-32.
19. Grimm M. Dipllng EE. Grabenwöger M. Griesmacher A. Losert U. Böck P. et al. Biocompatibilty of aldehyde-fixed bovine pericardium. An in vitro and in vivo approach toward improvement of bioprosthetic heart valves J Thorac Cardivasc Surg 1991; 102: 195-201.
20. Mako WJ, Calabro A, Ratliff NB, Vesely I. Loss of glycosaminoglycans (GAGs) from implanted bioprosthetic heart valves. Circulation 1997; 155: 863.
21. Iozzo RV. Matrix proteoglycans. From molecular design to cellular function. Annual Review in Biochemistry 1998; 67: 609-52.
22. Singla A, Lee CH. Inhibition of CEM calcification by the sequential pretreatment with Ethanol and EDTA. J Biomed Mater Res 2003; 64: 706-13.
23. Sierovegel MJ, De Klejin Pasterkamp DP, Strauss BH. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr Pharm Des 2003; 9: 1033-40.
24. Ernst E. Chelation therapy for coronary heart disease: An overview of all clinical investigations. Am Heart J, 2000; 140: 139-41.
25. Schick CH, Schwille PO. Studies on the reduction of aortic calcification by alcali citrates in an ex vivo tissue preparation in the rat. Drug Res 1993; 43: 831-5.
26. Simith RM, Martell AE. Critical stability constant. New York; Amines Plenum: 1975.
27. Armstrong C, Leong W, Lees GJ. Comparative affects of metal chelating agents on the neuronal cytotoxicity induced by copper (Cu+2), iron (Fe+3) and zinc in the hippocampus. Brain Res 2001; 892: 51-62.
28. Webster JM, Bentley MT, Wojcikiewicz RJH. N,N,N′,N′-Tetrakis(2-pyridylmethyl) ethylenediamine inhibits ligand binding to certain G protein-coupled receptors. Eur J Pharmacol 2003; 474: 1-5.
29. Wojcikiewicz RJH, Xu Q, Webster JM, Alzayady K, Gao C. Ubiquitination and proteasomal degradation of endogenous and exogenous inositol 1, 4, 5-triphospate receptors in αT3-1 anterior pituitary cells. J Biol Chem 2093; 278: 940-7.
30. Lorick DM, Jensen JP, Fang S, Ong AM, Hatakeyama S, Wiessman AM. RING fingers mediate ubiquitin-conjugating enzyme(E2)-dependent ubiquitination. Proc Natl Acad Sci 1996; 96: 11364-9.
31. Bays NW, Gardner RG, Seelig LP, Joazeiro CA, Hampton R. Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation. Nat. Cell Biol 2001; 3: 24-9.
32. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, at al. Aqueous dissolution af Alzheimer's disease Aβ amyloid deposits by biometal depletion. J Biol Chem 1999; 274: 23223-8.
33. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-76.
34. Karck M, Appelbaum Y, Schwalb H, Haverich A, Chevion M, Uretzky G. TPEN, a transition metal chelator, improves myocardial protection during prolonged ischemia. J Heart Lung Transplant 1992; 11: 979-85.